{"id":3278,"date":"2026-10-19T09:29:35","date_gmt":"2026-10-19T09:29:35","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=3278"},"modified":"2026-10-19T09:56:20","modified_gmt":"2026-10-19T09:56:20","slug":"omass-therapeutics-raises-310m","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/","title":{"rendered":"OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_312ee53c415f78534ea3aab48d460b51\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp 664w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics-300x169.webp 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics-475x267.webp 475w\" type=\"image\/webp\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As a provider of small molecule therapeutics for endocrinology and immunology, the company intends to use the funds to advance its lead program, OMS1620, through Phase 2 clinical development in congenital adrenal hyperplasia a genetic condition affecting hormone levels produced by the adrenal glands. The financing will also support OMass\u2019s work generating initial clinical data for a drug for lupus, the autoimmune disease, and other diseases associated with the overproduction of interferon proteins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The $310m (\u00a3230m) funding is the biggest in 2026 after the $2.1bn raised in May by Isomorphic Labs,&nbsp;with the funding round being co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and University of Oxford.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Led by CEO Ros Deegan she added: \u201cWe have demonstrated the ability of our team and approach to discover and deliver a pipeline of first and best-in-class programmes in endocrinology and immunology into the clinic.<\/p>\n\n\n    <section class=\"news-archive \" id=\"block_812a1bb666ac6fed057754203798113d\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg 1920w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-300x200.jpeg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1024x682.jpeg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-768x512.jpeg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1000x666.jpeg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\" target=\"_self\">\n\t\t\t\tBiotech Theolytics Relocates to ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-300x213.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1024x728.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-768x546.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1000x711.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tARC Launches Adapt by ARC at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/06\/09\/fluorok-secures-funding\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349.jpg 1536w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-300x130.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-1024x444.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-768x333.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-1000x434.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/06\/09\/fluorok-secures-funding\/\" target=\"_self\">\n\t\t\t\tFluoRok secures \u00a31.2M in funding strengthening the commercial proposition for the\u00a0 novel HF-free process for producing Fluorochemicals\u00a0\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing. As a provider of small molecule therapeutics for endocrinology and immunology, the company intends to use the funds to advance its lead program, OMS1620, through Phase 2 clinical development in congenital adrenal hyperplasia a genetic condition [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22,30],"tags":[4276,6210],"class_list":["post-3278","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-corporate","tag-science-and-innovation","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OMass Therapeutics Raises $310M in Series C Funding<\/title>\n<meta name=\"description\" content=\"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OMass Therapeutics Raises $310M in Series C Funding\" \/>\n<meta property=\"og:description\" content=\"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T09:29:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-19T09:56:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"664\" \/>\n\t<meta property=\"og:image:height\" content=\"373\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/person\\\/3a1b3eb8a7bd2232ae3f80a34598bd57\"},\"headline\":\"OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments\",\"datePublished\":\"2026-10-19T09:29:35+00:00\",\"dateModified\":\"2026-10-19T09:56:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/10\\\/Omass-Therapeutics.webp\",\"keywords\":[\"Science and innovation\",\"Life science and Health\"],\"articleSection\":[\"News\",\"Corporate\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/\",\"name\":\"OMass Therapeutics Raises $310M in Series C Funding\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/10\\\/Omass-Therapeutics.webp\",\"datePublished\":\"2026-10-19T09:29:35+00:00\",\"dateModified\":\"2026-10-19T09:56:20+00:00\",\"description\":\"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/10\\\/Omass-Therapeutics.webp\",\"contentUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/10\\\/Omass-Therapeutics.webp\",\"width\":664,\"height\":373},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/10\\\/19\\\/omass-therapeutics-raises-310m\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#website\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2025\\\/06\\\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2025\\\/06\\\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/person\\\/3a1b3eb8a7bd2232ae3f80a34598bd57\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/author\\\/rebeccafrost\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OMass Therapeutics Raises $310M in Series C Funding","description":"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/","og_locale":"en_US","og_type":"article","og_title":"OMass Therapeutics Raises $310M in Series C Funding","og_description":"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/","og_site_name":"ARC Oxford","article_published_time":"2026-10-19T09:29:35+00:00","article_modified_time":"2026-10-19T09:56:20+00:00","og_image":[{"width":664,"height":373,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp","type":"image\/webp"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57"},"headline":"OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments","datePublished":"2026-10-19T09:29:35+00:00","dateModified":"2026-10-19T09:56:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp","keywords":["Science and innovation","Life science and Health"],"articleSection":["News","Corporate"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/","name":"OMass Therapeutics Raises $310M in Series C Funding","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp","datePublished":"2026-10-19T09:29:35+00:00","dateModified":"2026-10-19T09:56:20+00:00","description":"OMass Therapeutics, an Oxford University Spin Out based at ARC Oxford has raised $310M (\u00a3230M) in Series C financing.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp","width":664,"height":373},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"OMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=3278"}],"version-history":[{"count":2,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3278\/revisions"}],"predecessor-version":[{"id":3282,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3278\/revisions\/3282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/3279"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=3278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=3278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=3278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}